Therapy for small cell lung cancer:review and prospect
- VernacularTitle:小细胞肺癌治疗回顾及展望
- Author:
Runbo ZHONG
;
Baohui HAN
- Publication Type:Journal Article
- Keywords:
lung neoplasms;
chemotherapy;
radiotherapy;
target therapy
- From:
China Oncology
2001;0(02):-
- CountryChina
- Language:Chinese
-
Abstract:
Small cell lung cancer(SCLC)is regarded as one of the most chemotherapy and radiotherapy sensitive malignant solid tumors.With regimens based on platinum-etoposide,which is still the standard of first-line treatment in extensive-stage SCLC,objective responses are seen in 50% to 70% of cases.With combined chemoradiotherapy,the probability of attaining a complete response increases to 40% to 50%.The majority of patients with SCLC will eventually develop a tumor relapse.For the patients with relapse,so far only single-agent topotecan represents a most effective therapeutic option.Integration of chest radiotherapy with standard chemotherapy,optimization of timing and fractionation of radiation therapy,and the introduction of prophylactic cranial radiation have led to an obvious improvement in 3-year survival.
